Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection

International Journal of Infectious Diseases

Volumn 12, Issue 3, 2008, Pages 252-255

  Ramezani, Amitis ^a,b   Velayati, Ali Akbar ^c   Roshan, Mohammad Reza Hasanjani ^d   Gachkar, Latif ^b   Banifazl, Mohammad ^e   Keyvani, Hossein ^f   Aghakhani, Arezoo ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e Iranian Society for Support of Patients with Infectious Diseases   (Iran)

^f Keyvan Virology Laboratory   (Iran)

Author keywords

Chronic hepatitis B; Lamivudine; PCR RFLP; YMDD motif mutants

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LIVER ENZYME;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IRAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD;

ADOLESCENT; ADULT; AMINO ACID MOTIFS; CHILD; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IRAN; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 42149173377     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2007.08.003     Document Type: Article

References (33)

1. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
2. Maddrey W.C. Hepatitis B-an important public health issue. Clin Lab 47 (2001) 51-55
3. Lok A.S., Lai C.L., Leung N., Yao G.B., Cui Z.Y., Schiff E.R., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
4. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
5. Heathcote J. Treatment of HBe antigen-positive chronic hepatitis B. Semin Liver Dis 23 (2003) 69-80
6. Hadziyannis S.J., Papatheodoridis G.V., and Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 23 (2003) 81-88
7. Wright T.L. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis 24 Suppl 1 (2004) 31-36
8. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27 (1998) 1670-1677
9. Tipples G.A., Ma M.M., Fischer K.P., Bain V.G., Kneteman N.M., and Tyrrell D.L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24 (1996) 714-717
10. Fu L., and Cheng Y.C. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L (-) SddC (3TC) resistance. Biochem Pharmacol 55 (1998) 1567-1572
11. Niesters H.G., Honkoop P., Haagsma E.B., de Man R.A., Schalm S.W., and Osterhaus A.D. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 177 (1998) 1382-1385
12. Lee C.Z., Lee H.S., Huang G.T., Yang P.M., and Sheu J.C. Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J Gastroenterol 12 (2006) 5301-5305
13. Matsuda M., Suzuki F., Suzuki Y., Tsubota A., Akuta N., Hosaka T., et al. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol 74 (2004) 361-366
14. Shin Y.M., Heo J., Kim G.H., Kang D.H., Song G.A., Cho M., et al. Natural YMDD motif mutations of HBV polymerase in the chronic hepatitis B virus infected patients. Taehan Kan Hakhoe Chi 9 (2003) 1-9
15. Leon P., Pozo F., and Echevarria J.M. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain. Enferm Infecc Microbiol Clin 22 (2004) 133-137
16. Brunt E.M. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 31 (2000) 241-246
17. Yang D.H., Liang W.F., Xie Y.J., Zhao N.F., and Fan J. PCR restriction fragment length polymorphism in detection of YMDD variants of viral polymerase in hepatitis B virus patients treated with lamivudine. Hepatobiliary Pancreat Dis Int 1 (2002) 232-237
18. Abdo A.A., Al-Jarallah B.M., Sanai F.M., Hersi A.S., Al-Swat K., Azzam N.A., et al. Hepatitis B genotypes: relation to clinical outcome in patients with chronic hepatitis B in Saudi Arabia. World J Gastroenterol 12 (2006) 7019-7024
19. Alavian S.M., Keyvani H., Rezai M., Ashayeri N., and Sadeghi H.M. Preliminary report of hepatitis B virus genotype prevalence in Iran. World J Gastroenterol 12 (2006) 5211-5213
20. Chayama K., Suzuki Y., Kobayashi M., Tsubota A., Hashimoto M., Miyano Y., et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27 (1998) 1711-1716
21. Allen M.I., Gauthier J., DesLauriers M., Bourne E.J., Carrick K.M., Baldanti F., et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 37 (1999) 3338-3347
22. Kirishima T., Okanoue T., Daimon Y., Itoh Y., Nakamura H., Morita A., et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 37 (2002) 259-265
23. Kobayashi S., Ide T., and Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 34 (2001) 584-586
24. Hyunjung J., Mong C., Jeong H., Hyunghoi K., Hongki J., Woowon S., et al. Oligonucleotide chip for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol 42 (2004) 4181-4188
25. Thibault V., Aubron-Olivier C., Agut H., and Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 16 (2002) 131-133
26. Yan M.H., Zhang C., Ling Q., and Zhou R.F. Detection of YMDD motif mutations in lamivudine-untreated patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 11 (2003) 430-431
27. Zhang X.H., Zhang Y.X., Sun L.R., Wen Q., Zhou L.Q., Fan G.X., et al. Study of gene chips in the detection of YMDD mutations in the region of HBV polymerase. Zhonghua Yi Xue Za Zhi 83 (2003) 459-462
28. Akarsu M., Sengonul A., Tankurt E., Sayiner A.A., Topalak O., Akpinar H., et al. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol 21 (2006) 1783-1788
29. Zhang X., Liu C., Gong Q., Zhang S., Zhang D., Lu Z., et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterol Hepatol 18 (2003) 1353-1357
30. Ye X.G., Wang R.L., and Guo H.B. Detection and analysis of YMDD mutated genes in patients of chronic hepatitis B before being treated. Zhonghua Jianyan Yixue Zazhi 25 (2002) 248
31. Huang Z.M., Huang Q.W., Qin Y.Q., He Y.Z., Qin H.J., Zhou Y.N., et al. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 11 (2005) 867-870
32. Heo J., Cho M., Kim H.H., Shin Y.M., Jang H.J., Park H.K., et al. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection. J Korean Med Sci 19 (2004) 541-546
33. Ou Z.Y., Liu N., Chen C.J., Cheng G., and He Y.S. Rapid and accurate genotyping of YMDD motif variants in the hepatitis B virus genome by an improved reverse dot blot method. J Clin Microbiol 43 (2005) 5685-5689